Overview
Strand Therapeutics, based in Cambridge, United States, has raised $153M in a Series B round on August 7, 2025, with participation from Kinnevik. The company programmable mRNA. The round will be used to accelerate product development, expand the team, and scale go-to-market operations.
Operating in the biotechnology research sector, Strand Therapeutics is positioned to capitalize on growing demand for innovative solutions in this space. The company was founded in 2017 by Jacob Becraft. Jacob brings deep domain expertise and a track record of execution that attracted investor confidence in this round. With fresh capital, the company is expected to invest heavily in R&D and talent acquisition, signaling a period of aggressive growth ahead.
Market Outlook
With $153M now on the balance sheet, Strand Therapeutics enters a new phase of growth that typically involves rapid hiring, technology upgrades, and vendor evaluations. For sales professionals and service providers, this represents a prime opportunity to engage while budget allocation decisions are being made and the team is actively building out its operational infrastructure.
Why contact Strand Therapeutics now
With $153M in fresh capital from Series B, Strand Therapeutics is entering a rapid growth phase. Post-funding startups typically increase headcount by 30-50% and begin evaluating new tools and services immediately. The founders and decision-makers are actively taking meetings right now — making this the perfect time to connect before their calendars fill up.
Founders & Contacts
Investors
Company Facts
| Company | Strand Therapeutics |
| Amount Raised | $153M |
| Funding Round | Series B |
| Date Raised | August 7, 2025 |
| Founded | 2017 |
| Industry | Biotechnology Research |
| Founders | Jacob Becraft |
| HQ Location | Cambridge, United States |
Get Verified Founder Emails
Access verified email addresses and contact details for Strand Therapeutics's founders and thousands of other funded startups.
Start Free Trial